Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Atripla (efavirenz + tenofovir disoproxil + emtricitabine)


Generic name: Atripla is a combination of the drugs efavirenz, tenofovir disoproxil and emtricitabine.

Brand names: Atripla

Class: Complete combination tablets


Very common (affecting more than 1 in 10 people): Dizziness, nausea, headache, diarrhoea, vomiting, rash, weakness, low blood phosphate levels, raised creatine kinase levels.

Common (affecting 1 in 100 people): Sleep disturbance, abnormal dreams, impaired concentration, dark patches of skin starting on the hands and soles of the feet, stomach pains, flatulence, bloating, liver problems, pancreas problems, low white blood cell count, increased triglycerides, bilirubin or sugar levels in the blood, anxiety, depression, allergic reaction, itching, co-ordination and balance problems, appetite loss, tiredness.

Uncommon (affecting up to 1 in 100 people): Psychiatric problems including psychosis and suicidal thoughts, kidney tubule damage, bone thinning, lactic acidosis, inflammation of the pancreas causing abdominal pain, liver inflammation, anaemia, allergic reaction (hypersensitivity) that can cause severe rash, forgetfulness, confusion, fitting, tremors, incoherent speech, swelling of the face, lips, tongue or throat, muscle pain, vertigo, ringing in the ears, blurred vision, breast enlargement in males, lowered sex drive, dry mouth, flushing, increased appetite, decreases in potassium in the blood, proteins in urine, increased cholesterol in the blood, increases in creatinine in the blood, softening of the bones, breakdown of muscle, chills.


Tablet comprises 600mg efavirenz, 200mg emtricitabine and 245mg tenofovir disoproxil.

Take one tablet once a day.


To minimise side-effects, take on an empty stomach (2 hours after a meal / 1 hour before a meal).

It's preferable to take it at bedtime.

*Last reviewed on 19/12/2016. Next review: 19/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM